Holen Sie sich die Stockscreener-App
1.07
4.50%
-0.04
Schlusskurs vom Vortag:
$1.11
Offen:
$1.11
24-Stunden-Volumen:
145.74K
Relative Volume:
0.35
Marktkapitalisierung:
$18.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.70M
KGV:
-0.3075
EPS:
-3.4798
Netto-Cashflow:
$-16.66M
1W Leistung:
+4.95%
1M Leistung:
-31.17%
6M Leistung:
-79.58%
1J Leistung:
-55.83%
1-Tages-Spanne:
$1.06
$1.12
1-Wochen-Bereich:
$0.96
$1.16
52-Wochen-Spanne:
$0.89
$13.48
Cel-Sci Corp. Stock (CVM) Company Profile
Firmenname
Cel-Sci Corp.
Sektor
Branche
Telefon
703-506-9460
Adresse
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
1.07 | 19.40M | 0 | -22.70M | -16.66M | -3.4798 |
VRTX
Vertex Pharmaceuticals Inc
|
493.95 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
633.37 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
894.00 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.17 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
185.02 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-02 | Eingeleitet | Dawson James | Buy |
Cel-Sci Corp. Aktie (CVM) Neueste Nachrichten
Why Did CEL-SCI Stock Plunge After Its Latest Offering - Kavout | AI
CVM: CEL-SCI Partners with Saudi Amarox for Multikine Launch - GuruFocus
CEL-SCI signs distribution deal with Saudi Amarox for Multikine - Investing.com
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care - The Joplin Globe
CEL-SCI Corp (CVM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CEL-SCI Corp (CVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CVM stock sinks in pre-market trading after announcing second equity raise for its cancer drug in just over a month - MSN
CEL-SCI Corp (CVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CEL-SCI Corp (CVM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CEL-SCI Corp (CVM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CEL-SCI Corp (CVM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BRIEF-CEL-SCI Announces Closing Of Offering - Dailyhunt
CEL-SCI Corp (CVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CEL-SCI Corp (CVM) Institutional Confidence - TradingKey
CEL-SCI Corp (CVM) Valuation: PE, PB & Fair Value Analysis - TradingKey
CEL-SCI Corporation Announces $2.5 Million Stock Offering to Advance Multikine Cancer Immunotherapy 1 - Minichart
CEL-SCI closes $2.5M stock offering at $1 per share By Investing.com - Investing.com South Africa
CEL-SCI (CVM) Advances Multikine for Head and Neck Cancer - GuruFocus
CEL-SCI Completes $2.5M Stock Offering at $1.00, Engages ThinkEquity as Placement Agent - TradingView
CEL-SCI (NYSE American: CVM) prices $2.5M best-efforts stock offering - Stock Titan
CEL-SCI closes $2.5M stock offering at $1 per share - Investing.com
CEL-SCI Announces Closing of Offering - Yahoo Finance
CEL-SCI to begin confirmatory study for head and neck cancer drug - Investing.com
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy - Yahoo Finance
[424B5] CEL SCI CORP Prospectus Supplement (Debt Securities) - Stock Titan
CEL-SCI Corporation (CVM) Prices Public Offering, Shares Drop in Premarket - GuruFocus
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month - Mena FN
CEL-SCI stock sale prices $2.5M to fund Multikine work - Stock Titan
CEL-SCI Corporation Announces Pricing of Offering - Yahoo Finance
CVM: CEL-SCI Partners with Saudi Amarox for Strategic Agreement - GuruFocus
CEL-SCI to formalize Saudi Arabia distribution agreement - Investing.com
Saudi cancer immunotherapy push brings CEL-SCI Multikine deal - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market SessionAditxt (NASDAQ:ADTX), Atossa Therapeutics - Benzinga
Cel-Sci Stock Slides 5.43% as Key Support Test LoomsBullish Pattern Stocks - newsline.com
CVM Technical Analysis | Trend, Signals & Chart Patterns | CEL-SCI CORP (NYSEARCA:CVM) - ChartMill
Cel-Sci (CVM) Holds Near Support as Biotech Stock Posts Modest GainChaikin Flow - newsline.com
CVM - Finviz
[RW] CEL SCI CORP SEC Filing - Stock Titan
CVM: CEL-SCI Advances Multikine Toward Regulatory Approval - GuruFocus
Cel Sci CEO Geert Kersten’s trust buys $360,000 in common stock By Investing.com - Investing.com South Africa
Cel Sci CEO Geert Kersten’s trust buys $360,000 in common stock - Investing.com Australia
Cel Sci Insider Bought Shares Worth $360,000, According to a Recent SEC Filing - marketscreener.com
CEL-SCI (NYSE: CVM) trust buys 300K restricted shares at $1.20 - Stock Titan
CEL-SCI adds Saudi partner, U.S. trial for head and neck cancer drug - Stock Titan
Cel-Sci: Fiscal Q2 Earnings Snapshot - cbs19news.com
CEL SCI CORP 1H 2026: Net loss $(10.94M), Diluted EPS $(1.35) — 10-Q Summary - TradingView
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 - marketscreener.com
CEL-SCI (NYSE: CVM) reports $10.9M loss and just $1.9M in cash - Stock Titan
CEL-SCI Partners with Amarox for Multikine Cancer Immunotherapy Commercialization in Saudi Arabia and GCC Region 12 - minichart.com.sg
CVM SEC FilingsCEL-SCI Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Finanzdaten der Cel-Sci Corp.-Aktie (CVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.46%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):